Comparison of cell lines for stable production of fucose‐negative antibodies with enhanced ADCC

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Biotechnology and Bioengineering

• Publication date

  2006-07-05

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1002/bit.20880PMID 16609957
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Engineering Chinese hamster ovary cells to maximize effector function of produced antibodies using FUT8 siRNA.

  2004influential reference
• Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2

  2004influential reference
• Establishment of FUT 8 Knockout Chinese Hamster Ovary Cells : An Ideal Host Cell Line for Producing Completely Defucosylated Antibodies With Enhanced Antibody-Dependent Cellular Cytotoxicity

  2004influential reference
• Enhancement of the Antibody-Dependent Cellular Cytotoxicity of Low-Fucose IgG1 Is Independent of FcγRIIIa Functional Polymorphism

  2004cited by this paper
• Establishment of FUT8 knockout Chinese hamster ovary cells: An ideal host cell line for producing completely defucosylated antibodies with enhanced antibody‐dependent cellular cytotoxicity

  2004influential reference
• Defucosylated Chimeric Anti-CC Chemokine Receptor 4 IgG1 with Enhanced Antibody-Dependent Cellular Cytotoxicity Shows Potent Therapeutic Activity to T-Cell Leukemia and Lymphoma

  2004cited by this paper
• Profiling analysis of oligosaccharides in antibody pharmaceuticals by capillary electrophoresis.

  2004cited by this paper
• The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity*

  2003influential reference
• Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to Human FcγRIII and Antibody-dependent Cellular Toxicity*

  2002influential reference
• Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene.

  2002influential reference
• Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets

  2000cited by this paper
• Dissection and optimization of immune effector functions of humanized anti-ganglioside GM2 monoclonal antibody.

  2000cited by this paper
• Molecular Cloning and Expression of GDP-d-mannose-4,6-dehydratase, a Key Enzyme for Fucose Metabolism Defective in Lec13 Cells*

  1998cited by this paper
• A high-throughput microscale method to release N-linked oligosaccharides from glycoproteins for matrix-assisted laser desorption/ionization time-of-flight mass spectrometric analysis.

  1998cited by this paper
• Molecular Cloning of Human GDP-mannose 4,6-Dehydratase and Reconstitution of GDP-fucose Biosynthesis in Vitro *

  1998cited by this paper
• Purification and cDNA Cloning of Porcine Brain GDP-L-Fuc:N-Acetyl-β-D-Glucosaminide α1→6Fucosyltransferase*

  1996cited by this paper
• Purification and cDNA cloning of porcine brain GDP-L-Fuc:N-acetyl-beta-D-glucosaminide alpha1-->6fucosyltransferase.

  1996cited by this paper
• Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies

  1993cited by this paper
• Systematic fractionation of oligosaccharides of human immunoglobulin G by serial affinity chromatography on immobilized lectin columns.

  1987influential reference
• Immunoglobulin G as a glycoprotein.

  1986cited by this paper
• Lectin-resistant CHO cells: Selection of four new pea lectin-resistant phenotypes

  1986cited by this paper
• Two Chinese hamster ovary glycosylation mutants affected in the conversion of GDP-mannose to GDP-fucose.

  1986influential reference
• Product-identification and substrate-specificity studies of the GDP-L-fucose:2-acetamido-2-deoxy-beta-D-glucoside (FUC goes to Asn-linked GlcNAc) 6-alpha-L-fucosyltransferase in a Golgi-rich fraction from porcine liver.

  1982cited by this paper
• Product-identification and substrate-specificity studies of the GDP-l-fucose: 2-acetamido-2-deoxy-β-d-glucoside (fuc→asn-linked GlcNAc) 6-α-l-fucosyltransferase in a golgi-rich fraction from porcine liver☆

  1982cited by this paper
• Structural and numerical variations of the carbohydrate moiety of immunoglobulin G.

  1982influential reference
• Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity.

  1980influential reference

• A gram-scale synthesis of β-L-carbafucose for engineering antibody glycans

  2025cites this paper
• Antibody glycan quality predicted from CHO cell culture media markers and machine learning

  2024cites this paper
• A metabolic inhibitor blocks cellular fucosylation and enables production of afucosylated antibodies

  2024cites this paper
• Combinatory glycoengineering of monoclonal antibodies and its application in cancer therapy: a narrative review

  2023cites this paper
• Receptor-mediated drug delivery of bispecific therapeutic antibodies through the blood-brain barrier

  2023cites this paper
• Establishment of Membrane-Bound IgA1-Specific Antibody Possessing Antibody-Dependent Cellular Cytotoxicity Activity

  2022cites this paper
• Biotherapeutics ADME and PK/PD Principles

  2022cites this paper
• Rapid Antibody Glycoengineering in CHO Cells Via RNA Interference and CGE-LIF N-Glycomics.

  2021cites this paper
• Glycoengineering Chinese hamster ovary cells: a short history

  2021cites this paper
• Physicochemical analysis and biological characterization of FKB327 as a biosimilar to adalimumab

  2020cites this paper
• Acute and Chronic Dosing of a High-Affinity Rat/Mouse Chimeric Transferrin Receptor Antibody in Mice

  2020cites this paper
• Traces matter: Targeted optimization of monoclonal antibody N‐glycosylation based on/by implementing automated high‐throughput trace element screening

  2020cites this paper
• How to select IgG subclasses in developing anti-tumor therapeutic antibodies

  2020cites this paper
• A novel bicistronic gene design couples stable cell line selection with a fucose switch in a designer CHO host to produce native and afucosylated glycoform antibodies

  2018cites this paper
• Antibody glycoengineering strategies in mammalian cells

  2018cites this paper
• The “less-is-more” in therapeutic antibodies: Afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity

  2018cites this paper
• Improving Immunotherapy Through Glycodesign

  2018cites this paper
• Immune Correlate-Guided HIV Vaccine Design.

  2018influential citation
• Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy

  2018cites this paper
• Fc engineering of anti-Nectin-2 antibody improved thrombocytopenic adverse event in monkey

  2018cites this paper
• Comprehensive N-Glycan Profiling of Cetuximab Biosimilar Candidate by NP-HPLC and MALDI-MS

  2017cites this paper
• Lentiviral vector packaging cell line development using genome editing to target optimal loci discovered by high throughput DNA barcoding

  2017cites this paper
• Improving Antibody-Based Cancer Therapeutics Through Glycan Engineering

  2017cites this paper
• Current progress in innovative engineered antibodies

  2017cites this paper
• Development of a pre-glycoengineered CHO-K1 host cell line for the expression of antibodies with enhanced Fc mediated effector function

  2017influential citation
• Identifying the differences in mechanisms of mycophenolic acid controlling fucose content of glycoproteins expressed in different CHO cell lines

  2016cites this paper
• Cell Surface Antibody Retention Influences In Vivo Antitumor Activity Mediated by Antibody-dependent Cellular Cytotoxicity.

  2016cites this paper
• Immune recruitment or suppression by glycan engineering of endogenous and therapeutic antibodies

  2016cites this paper
• Functional knockout of FUT8 in Chinese hamster ovary cells using CRISPR/Cas9 to produce a defucosylated antibody

  2015cites this paper
• Enzymatic functionalization of a nanobody using protein insertion technology.

  2015cites this paper
• Antibody glycosylation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and Fc-fusion proteins.

  2015cites this paper
• Amino acid and glucose metabolism in fed‐batch CHO cell culture affects antibody production and glycosylation

  2015cites this paper
• N-Glycosylation Fingerprinting of Viral Glycoproteins by xCGE-LIF.

  2015cites this paper
• Pr1E11, a novel anti-TROP-2 antibody isolated by adenovirus-based antibody screening, recognizes a unique epitope.

  2015cites this paper
• Challenges with afucosylation content in antibody‐based drugs: Guidance provided by mathematical modeling

  2015influential citation
• Assignment of Core versus Antenna Fucosylation Types in Protein N-Glycosylation via Procainamide Labeling and Tandem Mass Spectrometry.

  2015cites this paper
• Anti-human platelet antigen (HPA)-1a antibodies: For better or for worse

  2015cites this paper
• GlycoDelete engineering of mammalian cells simplifies N-glycosylation of recombinant proteins

  2014cites this paper
• Investigation of the correlation between charge and glycosylation of IgG1 variants by liquid chromatography-mass spectrometry.

  2014influential citation
• Sialic acid methylation refines capillary electrophoresis laser‐induced fluorescence analyses of immunoglobulin G N‐glycans of ovarian cancer patients

  2014cites this paper
• Highly robust protein production by co-culture of CHO spheroids layered on feeder cells in serum-free medium

  2014cites this paper
• Mammalian cell line developments in speed and efficiency.

  2014cites this paper
• Targeting the Fc receptor in autoimmune disease

  2014cites this paper
• Rapid Assays for Lectin Toxicity and Binding Changes that Reflect Altered Glycosylation in Mammalian Cells

  2014cites this paper
• Clinical Development of Antibody-Fusion Proteins for Cancer Therapy

  2014cites this paper
• Do YB2/0 cells produce alien sugars?

  2013cites this paper
• Multiarray formation of CHO spheroids cocultured with feeder cells for highly efficient protein production in serum-free medium.

  2013cites this paper
• Chapter 10 - Antibody glycosylation

  2013cites this paper
• Separation of nonfucosylated antibodies with immobilized FcγRIII receptors

  2013cites this paper
• Is an expression system for producing therapeutic antibodies with immunosuppressive properties found at last? Comment to letter by Dr. Quagliaroli

  2013cites this paper
• The impact of cell adaptation to serum-free conditions on the glycosylation profile of a monoclonal antibody produced by Chinese hamster ovary cells.

  2013influential citation
• Engineering Chinese hamster ovary (CHO) cells for producing recombinant proteins with simple glycoforms by zinc-finger nuclease (ZFN)-mediated gene knockout of mannosyl (alpha-1,3-)-glycoprotein beta-1,2-N-acetylglucosaminyltransferase (Mgat1).

  2013cites this paper
• Rapid Generation of Stable Cell Lines Expressing High Levels of Erythropoietin, Factor VIII, and an Antihuman CD20 Antibody Using Lentiviral Vectors

  2013cites this paper
• Characterization of N-Linked Glycosylation in a Monoclonal Antibody Produced in NS0 Cells Using Capillary Electrophoresis with Laser-Induced Fluorescence Detection

  2013cites this paper
• Advantages of AlaGln as an additive to cell culture medium: use with anti-CD20 chimeric antibody-producing POTELLIGENT™ CHO cell lines

  2012cites this paper
• Development and validation of an antibody-dependent cell-mediated cytotoxicity-reporter gene assay

  2012cites this paper
• Mogamulizumab for the treatment of adult T-cell leukemia/lymphoma.

  2012cites this paper
• Fucose content of monoclonal antibodies can be controlled by culture medium osmolality for high antibody-dependent cellular cytotoxicity

  2012cites this paper
• Impact on N-Glycosylation profile of monoclonal anti-D antibodies as a way to control their immunoregulatory and cytotoxic properties

  2012cites this paper
• Fc engineering: design, expression, and functional characterization of antibody variants with improved effector function.

  2012cites this paper
• Structural biology of IgG Fc glycoforms

  2012cites this paper
• Assessment of the interactions between bioprocess conditions and protein glycosylation in antibody-producing mammalian cell cultures

  2012cites this paper
• Anti-RhD-Mediated Immunosuppression: Can Monoclonal Antibodies Imitate the Action of Polyclonal Antibodies?

  2012cites this paper
• Analysis of carbohydrates and glycoconjugates by matrix-assisted laser desorption/ionization mass spectrometry: an update for the period 2005-2006.

  2011cites this paper
• Neuroprotection with a Brain-Penetrating Biologic Tumor Necrosis Factor Inhibitor

  2011cites this paper
• Molecular cloning, characterization, genomic organization and promoter analysis of the α1,6-fucosyltransferase gene (fut8) expressed in the rat hybridoma cell line YB2/0

  2011influential citation
• Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC.

  2011cites this paper
• Glycoengineered Pichia produced anti-HER2 is comparable to trastuzumab in preclinical study

  2011cites this paper
• Optimizing Therapeutic Antibody Function

  2011cites this paper
• Molecular cloning , characterization , genomic organization and promoter analysis of the a 1 , 6-fucosyltransferase gene ( fut 8 ) expressed in the rat hybridoma cell line YB 2 / 0

  2011influential citation
• The Role of Glycosylation in Therapeutic Antibodies

  2011cites this paper
• Engineering Antibodies for Cancer Therapy

  2011cites this paper
• Cell Line Isolation and Design

  2011cites this paper
• Protein glycosylation: Analysis, Characterization, and Engineering

  2011cites this paper
• GlycoFi's technology to control the glycosylation of recombinant therapeutic proteins

  2010cites this paper
• Production of non-fucosylated antibodies by co-expression of heterologous GDP-6-deoxy-D-lyxo-4-hexulose reductase.

  2010cites this paper
• Advantage of Alagln as an Additive to Cell Culture Medium

  2010cites this paper
• Defucosylated Humanized Anti-CCR4 Monoclonal Antibody KW-0761 as a Novel Immunotherapeutic Agent for Adult T-cell Leukemia/Lymphoma

  2010cites this paper
• Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma.

  2010cites this paper
• Engineering mammalian cells in bioprocessing – current achievements and future perspectives

  2010cites this paper
• Rapid production of recombinant human IgG With improved ADCC effector function in a transient expression system

  2010cites this paper
• Towards the implementation of quality by design to the production of therapeutic monoclonal antibodies with desired glycosylation patterns

  2010cites this paper
• EB66 cell line, a duck embryonic stem cell-derived substrate for the industrial production of therapeutic monoclonal antibodies with enhanced ADCC activity

  2010cites this paper
• Antibody Glycans Characterization

  2010cites this paper
• Glycoengineering of Monoclonal Antibodies

  2010cites this paper
• Plant-specific glycosylation patterns in the context of therapeutic protein production.

  2010cites this paper
• Analytical Characterization of Monoclonal Antibodies: Linking Structure to Function

  2010cites this paper
• Production of therapeutic antibodies with controlled fucosylation

  2009cites this paper
• Change in glycosylation pattern with extension of endoplasmic reticulum retention signal sequence of mouse antibody produced by suspension-cultured tobacco BY2 cells.

  2009cites this paper
• Effect of Producer Cell Line on Functional Activity of Anti-D Monoclonal Antibodies Destined for Prevention of Rhesus Sensitization

  2009cites this paper
• Short‐hairpin‐RNA‐mediated silencing of fucosyltransferase 8 in Chinese‐hamster ovary cells for the production of antibodies with enhanced antibody immune effector function

  2009cites this paper
• Glycomics Profiling of Chinese Hamster Ovary Cell Glycosylation Mutants Reveals N-Glycans of a Novel Size and Complexity*

  2009cites this paper
• [Potelligent antibodies as next generation therapeutic antibodies].

  2009cites this paper
• Improving effector functions of antibodies for cancer treatment: Enhancing ADCC and CDC

  2008cites this paper
• The way forward, enhanced characterization of therapeutic antibody glycosylation: comparison of three level mass spectrometry-based strategies.

  2008cites this paper
• Development and production of commercial therapeutic monoclonal antibodies in Mammalian cell expression systems: an overview of the current upstream technologies.

  2008cites this paper
• Evaluation of glycosylation for quality assurance of antibody pharmaceuticals by capillary electrophoresis

  2008cites this paper
• Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins.

  2008cites this paper
• Effect of mannose chain length on targeting of glucocerebrosidase for enzyme replacement therapy of Gaucher disease.

  2007cites this paper
• Double knockdown of α1,6-fucosyltransferase (FUT8) and GDP-mannose 4,6-dehydratase (GMD) in antibody-producing cells: a new strategy for generating fully non-fucosylated therapeutic antibodies with enhanced ADCC

  2007cites this paper